64Cu-PSMA I&T

DRUG3 trials

Sponsors

Curium US LLC

Conditions

Metastasis From Malignant Tumor of Prostate (Disorder)Prostate cancer

Phase 2

Cu-64-PSMA-I&T Positron Emission Tomography (PET) Imaging of Metastatic PSMA Positive Lesions in Men With Prostate Cancer

CompletedNCT05653856

Curium US LLCMetastasis From Malignant Tumor of Prostate (Disorder)

Start: 2022-12-05End: 2023-05-17Updated: 2025-01-24

Phase 3

A Phase 3, Multicenter, Open-label Study to Test the Diagnostic Performance of Copper Cu 64 PSMA I&T PET/CT in Staging of Men with Newly Diagnosed Unfavorable Intermediate-risk, High-risk or Very High-risk Prostate Cancer Electing to Undergo Radical Prostatectomy with Pelvic Lymph Node Dissection

WithdrawnCTIS2024-512754-16-00

Curium US LLCProstate cancer

Target: 150Updated: 2024-09-23

A Phase 3, Multicenter, Open-label Study to Test the Diagnostic Performance of Copper Cu 64 PSMA I&T PET/CT in Staging of Men with Newly Diagnosed Unfavorable Intermediate-risk, High-risk or Very High-risk Prostate Cancer Electing to Undergo Radical Prostatectomy with Pelvic Lymph Node Dissection

CompletedCTIS2024-512754-16-01

Curium US LLCProstate cancer

End: 2025-02-04Target: 150Updated: 2025-01-20